"""
Question: 1101 

Evidence: In the first national-scale study of the PDR prevalence, it was found to be relatively low (2.96%). In this article, the results of the final analysis of all the sequences obtained in this HIVDR study are presented.

Rationale: The paper explicitly states it is the first national-scale study of PDR in Uzbekistan and presents final analyses of sequences from this study, indicating the data were previously unpublished.

Answer: Yes
"""

"""
Question: 1102 

Evidence: HIV-1 genome pol region viral sequences were obtained from 309 patients, of those 106 on ART and 203 on ART-initiators. In total, 309 nucleotide sequence consensuses with a length of 911--1,238 bp had been obtained for mutation and subtype analysis in both cohorts.

Rationale: The text clearly indicates that HIV-1 sequences (pol region) were generated from patient samples.

Answer: Yes
"""

"""
Question: 1103 

Evidence: HIV-1 pol genome region sequencing was performed at the Laboratory of Molecular Genetic Analysis of the Research Institute of Virology. The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs) among the ART-experienced populations.

Rationale: Methods describe only sequencing and genotypic analysis; there is no mention of any in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs) among the ART-experienced populations. The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: Only genotypic tools were used; the paper does not report any phenotypic susceptibility assays or IC measurements.

Answer: No
"""

"""
Question: 2101 

Evidence: The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263. Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016 with informed consent.

Rationale: The paper explicitly lists GenBank accession numbers for the patient-derived sequences.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016 with informed consent. The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The sequences were derived from clinical plasma specimens (not laboratory strains) and deposited to GenBank.

Answer: Yes
"""

"""
Question: 2103 

Evidence: The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The paper provides a comprehensive list of accession numbers for all deposited sequences.

Answer: MF401457–MF401512; MF431622–MF431713; MF431717; MF431719; MF497081; MF497088; MF497090–MF497219; MF497220; MF497222–MF497262; MF497263
"""

"""
Question: 2202 

Evidence: Among the 203 sequences, 6 samples were found, each of which contained 1 mutation from the list of surveillance mutations (2.96%). The most common NRTI resistance mutations were M184V/I (49.1%; 52/106), A62V (36.8%; 39/106), and K65R (18.9%; 20/106) mutations followed by Y115F (6.6%; 7/106), L74I (6/106), and M41L (5.7%; 6/106).

Rationale: The paper reports aggregate prevalence of mutations and not per-isolate mutation lists.

Answer: No
"""

"""
Question: 2301 

Evidence: To evaluate the national prevalence of antiretroviral therapy (ART)-resistant HIV-1 viruses among both ART-initiators (pretreatment drug resistance, PDR) and ART-failure HIV patients in Uzbekistan. HIV-1 genome pol region viral sequences were obtained from 309 patients.

Rationale: The species studied is explicitly HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: According to the REGA interpretation, most of the viruses were recognized as circulating recombinant form CRF02_AG (176/309, 57.0%). There were four additional subtypes identified: 125 (40.5%) viruses belonged to subtype A1, 3---to subtype B, 2 were defined as recombinant of A1, G, and one to subtype C. Two sequences were preliminarily considered unique recombinant forms (URFs) between subtype A1 and CRF02_AG.

Rationale: The paper lists the subtypes and recombinant forms identified among sequenced viruses.

Answer: CRF02_AG; A1 (also referred to as A6 in Table 5); subtype B; subtype C; recombinant A1/G; unique recombinant forms between A1 and CRF02_AG
"""

"""
Question: 2303 

Evidence: Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained and further evaluated for DRMs. HIV-1 pol genome region sequencing was performed at the Laboratory of Molecular Genetic Analysis of the Research Institute of Virology.

Rationale: The sequenced regions are the protease (PR) and reverse transcriptase (RT) within the pol gene.

Answer: Protease (PR) and Reverse Transcriptase (RT) regions of pol
"""

"""
Question: 2304 

Evidence: HIV-1 genome pol region viral sequences were obtained from 309 patients. Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained and further evaluated for DRMs.

Rationale: The study reports results from pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: A nation-wide, cross-sectional active HIV-1 PDR surveillance was conducted in Uzbekistan from 2015 to 2016. Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016.

Rationale: The study was conducted nationally in Uzbekistan.

Answer: Uzbekistan
"""

"""
Question: 2402 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016. The genotyping analysis of the samples collected in 2015–2016 was performed in subsequent years (2017–2019).

Rationale: The collection period is explicitly stated.

Answer: 2015–2016 (May 2015 to January 2016)
"""

"""
Question: 2502 

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: Use of the Applied Biosystems 3500xL with primers indicates Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers. HIV-1 pol genome region sequencing was performed at the Laboratory of Molecular Genetic Analysis of the Research Institute of Virology.

Rationale: The methods indicate Sanger sequencing and do not mention any NGS technology.

Answer: No
"""

"""
Question: 2504 

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: The workflow describes direct amplification and sequencing; there is no mention of cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers. HIV-1 pol genome region sequencing was performed at the Laboratory of Molecular Genetic Analysis of the Research Institute of Virology.

Rationale: The method describes bulk population sequencing using primers, not single genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: No molecular cloning procedures are described; sequencing was performed directly on amplified products.

Answer: No
"""

"""
Question: 2601 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016 with informed consent. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: Sequencing was performed on plasma viral RNA.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016 with informed consent. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: Only plasma specimens and viral RNA are mentioned; no PBMC DNA sequencing is reported.

Answer: No
"""

"""
Question: 2603 

Evidence: HIV-1 genome pol region viral sequences were obtained from 309 patients, of those 106 on ART and 203 on ART-initiators. In total, 309 nucleotide sequence consensuses with a length of 911--1,238 bp had been obtained for mutation and subtype analysis in both cohorts.

Rationale: All reported sequences were derived from plasma specimens.

Answer: 309
"""

"""
Question: 2604 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016. HIV-1 genome pol region viral sequences were obtained from 309 patients.

Rationale: There is no mention of PBMC sequencing; therefore, the number is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: The enrollment criteria for the cohort I (PDR) included that the patients provide informed consent, ≥18 years, and with viral load ≥1,000 copies/mL. Recruitment of patients with ART failure (cohort II) ... criteria: ≥18 years, viral load ≥1,000 copies/mL at the time of enrollment.

Rationale: Both cohorts required detectable plasma viremia ≥1,000 copies/mL, indicating active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016. The extraction of viral RNA and further amplification were performed using the AmpliSense HIV Genotype EPh kit.

Rationale: Sequencing was performed on plasma viral RNA, not on proviral DNA, so not from the proviral reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: The enrollment criteria for the cohort I (PDR) included that the patients provide informed consent, ≥18 years. Recruitment of patients with ART failure (cohort II) ... criteria: ≥18 years.

Rationale: Only adults were included; no infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: A nation-wide, cross-sectional active HIV-1 PDR surveillance was conducted in Uzbekistan from 2015 to 2016. A simple questionnaire with essential data ... was applied to each case before blood specimen withdrawal.

Rationale: The study is an observational surveillance, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: A nation-wide, cross-sectional active HIV-1 PDR surveillance was conducted in Uzbekistan from 2015 to 2016. Recruitment of patients with ART failure (cohort II) was carried out in the same clinics as PDR patients.

Rationale: The study is not a clinical trial; therefore, not all individuals were in a trial.

Answer: No
"""

"""
Question: 3101 

Evidence: HIV-1 genome pol region viral sequences were obtained from 309 patients, of those 106 on ART and 203 on ART-initiators. In total, 309 nucleotide sequence consensuses ... had been obtained for mutation and subtype analysis in both cohorts.

Rationale: The number of individuals with sequences is explicitly stated.

Answer: 309
"""

"""
Question: 3102 

Evidence: Of totally enrolled 713 patients, there were 344 HIV-positive adults enrolled into the PDR study (cohort I) and 369 into the ADR study (cohort II). In total, 309 nucleotide sequence consensuses ... had been obtained for mutation and subtype analysis in both cohorts.

Rationale: Not all enrolled individuals had sequences obtained.

Answer: No
"""

"""
Question: 4101 

Evidence: Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained and further evaluated for DRMs. The enrollment criteria for the cohort I (PDR) included ... ART-naive patients initiating ART.

Rationale: Cohort I consisted of ART-naive individuals and sequences were obtained.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Of the 369 cohort II samples analyzed, 106 sequences were obtained. Recruitment of patients with ART failure (cohort II) ... being on ART for more than 12 months and still on ART at the time of enrollment.

Rationale: Sequences were also obtained from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: HIV-1 genome pol region viral sequences were obtained from 309 patients, of those 106 on ART and 203 on ART-initiators. Of 344 samples analyzed, 203 cohort I sequences ... and ... Of the 369 cohort II samples analyzed, 106 sequences were obtained.

Rationale: The study includes sequences from both ART-naive and ART-experienced patients.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained and further evaluated for DRMs. The enrollment criteria for the cohort I (PDR) included ... ART-naive patients initiating ART.

Rationale: The paper reports 203 sequences from ART-naive individuals.

Answer: 203
"""

"""
Question: 4105 

Evidence: A simple questionnaire with essential data ... and antiretroviral therapy history for the ART failure - aquired drug resistance (ADR) cohort, was applied to each case. Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens ... (Table 2).

Rationale: The paper provides summary regimen information and indicates ART history was collected for the ADR cohort, but it does not provide complete, detailed ART history for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: Among the 203 sequences, 6 samples were found, each of which contained 1 mutation from the list of surveillance mutations (2.96%). In the first national-scale study of the PDR prevalence, it was found to be relatively low (2.96%).

Rationale: Transmitted (pretreatment) resistance prevalence among ART-naive initiators is reported.

Answer: Yes
"""

"""
Question: 4202 

Evidence: The first task of this program was the assessment of HIVDR mutation prevalence among HIV-positive people initiating ART (pretreatment drug resistance, PDR). Among the 203 sequences, 6 samples were found ... (2.96%).

Rationale: The study explicitly measures and reports the prevalence of pretreatment drug resistance.

Answer: Yes
"""

"""
Question: 4301 

Evidence: The main therapy regimens used as first-line therapy in Uzbekistan were as follows: tenofovir (TDF)/zidovudine (AZT)/abacavir (ABC)+emtricitabine (FTC)/lamivudine (3TC) as the NRTI backbone; efavirenz (EFV)/nevirapine (NVP) as the third NNRTI drug were administered to 100% of the patients. The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%).

Rationale: The drug classes used include NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, and PIs
"""

"""
Question: 4302 

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used. Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv.

Rationale: The paper notes that integrase inhibitors (raltegravir or dolutegravir) were used in 4% of patients at that time, indicating information on individuals receiving INSTIs is reported.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%).

Rationale: The study reports on individuals receiving PI-based regimens (LPV/rtv).

Answer: Yes
"""

"""
Question: 4304 

Evidence: Table 2. Distribution of Regimens in the Study. The main therapy regimens used as first-line therapy in Uzbekistan were ... with various NRTI backbones and EFV/NVP as third drugs, and PI-based second-line regimens.

Rationale: Multiple different ART regimens were used; therefore, not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. Table 2 shows regimen distributions limited to NRTIs, NNRTIs, and LPV-based PIs without listing INSTIs.

Rationale: The regimens reported for study participants do not include integrase inhibitors, indicating participants were INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens.

Rationale: Being on second-line therapy implies these 54 individuals had received more than one ART regimen.

Answer: 54
"""

"""
Question: 4404 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens.

Rationale: The paper does not report how many individuals received more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. Table 2 shows multiple different regimens across participants.

Rationale: Since some were on second-line and others on first-line, not all individuals received the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens.

Rationale: At least 54 individuals had more than one regimen; therefore, not all had only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used. Table 2 lists regimens and does not include dolutegravir-containing regimens.

Rationale: The paper mentions that INSTIs (RAL or DTG) were used in 4% of patients generally but does not specify how many individuals in the study received dolutegravir.

Answer: NA
"""

"""
Question: 4502 

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%). Table 2 lists PI regimens as LPV-based without mention of darunavir.

Rationale: Darunavir is not reported among the regimens; therefore, the number is zero.

Answer: 0
"""

"""
Question: 5101 

Evidence: Among the 203 sequences, 6 samples were found, each of which contained 1 mutation from the list of surveillance mutations (2.96%). Of the 369 cohort II samples analyzed, 106 sequences were obtained. Of them, 82 contained at least one mutation against PI, NRTI, or NNRTI drugs (77.4%, 82/106).

Rationale: Summing individuals with at least one DRM across both cohorts yields 6 (PDR) + 82 (ADR) = 88.

Answer: 88
"""

"""
Question: 5102 

Evidence: Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained. The most common NRTI resistance mutations were M184V/I, A62V, and K65R ... Among the NNRTI mutations, the most frequently identified were ... K103N, G190S, K101E, and Y181C.

Rationale: Only PR and RT regions were sequenced; integrase was not analyzed, so INSTI-resistance mutations were not assessed.

Answer: NA
"""

"""
Question: 5103 

Evidence: The most common NRTI resistance mutations were M184V/I (49.1%; 52/106), A62V (36.8%; 39/106), and K65R (18.9%; 20/106). Among the thymidine analogue mutations (TAMs) ... accounted for 18.9% (20/106 of all samples).

Rationale: K65R is the primary mutation associated with TDF resistance; it occurred in 20 individuals.

Answer: 20
"""

"""
Question: 5104 

Evidence: Of 344 samples analyzed, 203 cohort I sequences of RT and PR HIV-1 pol regions have been obtained. The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs) among the ART-experienced populations.

Rationale: Integrase was not sequenced or analyzed; no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: The paper reports only genotypic analyses; no phenotypic susceptibility test method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: No IC50/IC90 data are presented.

Answer: No
"""

"""
Question: 6103 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: The study does not include phenotypic assays or report IC50 fold changes.

Answer: No
"""

"""
Question: 6104 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: No phenotypic susceptibility assay was performed.

Answer: NA
"""

"""
Question: 6105 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: Replication capacity data are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs). The Calibrated Population Resistance (CPR) tool was used to assess the PDR prevalence.

Rationale: No phenotypic susceptibility testing was performed; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016. HIV-1 pol genome region sequencing was performed ... Sequencing ... using six primers.

Rationale: The study sequenced clinical samples; there is no indication of site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102 

Evidence: HIV-1 pol genome region sequencing was performed ... The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs).

Rationale: No in vitro passage experiments are described; the study relies on sequencing and genotypic analysis.

Answer: No
"""